DTC Print Ads: Package Insert Info Is Out, Drug Facts Box Is In
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s revised draft guidance for disclosing risk information in direct-to-consumer print ads advises against the use of package insert information in the brief summary; suggests Drugs Facts box or Q&A as alternative formats.
You may also be interested in...
FDA's Rx Promotion Citation Drought Continued In 2015
First Amendment litigation and guidance document work may be factors behind decline.
DTC Print Ads: NEJM, Industry Critique FDA Guidance For Clarifying Risk Info
Article suggests that a Drug Facts box could specify the proportion of patients who benefitted from the drug in key trials and how many had adverse events; PhRMA calls for revision to regulations, preclearance regime.
FDA "Brief Summary" Changes Should Be Written In Regs - PhRMA
DTC draft guidance creates a regulatory "Catch-22" by going against current regulations, PhRMA says in comments. FDA's guidance on disease awareness ads oversteps the agency's authority in regulating unbranded ads, the group asserts.